All In Biotech

Drug Trial Radar · NCT02783482

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

Last checked: Nov 19, 2026Latest source record: Dec 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

49

Actual

Start

Oct 2016

Primary completion

Jul 2019

Study completion Jul 2019

Sponsor

Lead sponsor
Green Cross CorporationIndustry
Sponsor type
Industry
Collaborators
Parexel; Atlantic Research Group
First posted
May 26, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in subjects with Primary Humoral Immunodeficiency (PHID).

Conditions

  • Immunologic Deficiency Syndromes

Interventions

  • GC5107Biological

    GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Incidence of Acute Serious Bacterial Infections (SBI)Time frame: One year
  2. The Proportion of Infusions With Temporally Associated Adverse Events (TAAEs) That Occur Within 72 Hours Following an Infusion of Test ProductTime frame: Within 72 hours after an infusion of GC5107

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • Immuno International Research Centers

    Centennial, Colorado

  • Allergy Associates of Palm Beaches PA

    North Palm Beach, Florida

  • Midwest Immunology Clinic and Infusion Center

    Plymouth, Minnesota

  • Optimed Infusions LLC

    Columbus, Ohio

  • Oklahoma Institute of Allergy Ashma and Immunology

    Oklahoma City, Oklahoma

  • Allergy Partners of North Texas Research

    Dallas, Texas

  • Allergy and Asthma Specialists

    Dallas, Texas

  • Pediatric Pulmonary Associates of North Texas

    Frisco, Texas

  • Allergy Asthma and Immunology Clinic PA

    Irving, Texas

  • Lysosomal Rare Disorder Research and Treatment Center, Inc.

    Fairfax, Virginia

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • Hamilton Health Sciences Corporation

    Hamilton, Ontario, Canada

  • Queen's University - Kingston General Hospital (KGH)

    Kingston, Ontario, Canada

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • Gordon Sussman Clinical Research

    Toronto, Ontario, Canada

  • Saint Michael's Hospital

    Toronto, Ontario, Canada

  • Hotel Dieu de Montreal

    Montreal, Quebec, Canada

  • CHU Ste-Justine - University of Montreal

    Montreal, Quebec, Canada

  • McGill University Health Centre (MUHC) - The Montreal Children's Hospital

    Montreal, Quebec, Canada

  • Clinique Spécialisée en Allergie de la Capitale

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.